$CAPR
CAPRICOR THERAPEUTICS, INC.

2023 Q2 Form 10-Q Financial Statement

#000155837023009521 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $3.917M $2.987M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.847M $3.510M
YoY Change 20.82% 29.24%
% of Gross Profit
Research & Development $8.800M $7.700M
YoY Change 76.0% 50.98%
% of Gross Profit
Depreciation & Amortization $254.7K $230.1K
YoY Change 127.39% 148.78%
% of Gross Profit
Operating Expenses $11.66M $11.17M
YoY Change 59.32% 42.65%
Operating Profit -$7.747M -$8.185M
YoY Change 5.81% 4.51%
Interest Expense $380.7K $416.4K
YoY Change 1649.45% 2998.51%
% of Operating Profit
Other Income/Expense, Net $380.7K $416.4K
YoY Change 79.28% 2998.53%
Pretax Income -$7.367M -$7.768M
YoY Change 3.62% -0.64%
Income Tax
% Of Pretax Income
Net Earnings -$7.367M -$7.768M
YoY Change 3.62% -0.64%
Net Earnings / Revenue -188.04% -260.1%
Basic Earnings Per Share -$0.29 -$0.31
Diluted Earnings Per Share -$0.29 -$0.31
COMMON SHARES
Basic Shares Outstanding 25.27M 25.26M
Diluted Shares Outstanding 25.34M 25.25M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.79M $45.17M
YoY Change -26.5% -22.56%
Cash & Equivalents $9.837M $10.61M
Short-Term Investments $27.96M $34.57M
Other Short-Term Assets $583.8K $875.1K
YoY Change -11.44% -7.23%
Inventory
Prepaid Expenses
Receivables $547.6K $547.6K
Other Receivables $0.00 $0.00
Total Short-Term Assets $38.92M $46.59M
YoY Change -26.03% -21.87%
LONG-TERM ASSETS
Property, Plant & Equipment $4.790M $4.811M
YoY Change 82.18% 106.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $268.2K $268.2K
YoY Change 0.0% -2.74%
Total Long-Term Assets $7.086M $7.269M
YoY Change 30.22% 37.47%
TOTAL ASSETS
Total Short-Term Assets $38.92M $46.59M
Total Long-Term Assets $7.086M $7.269M
Total Assets $46.01M $53.86M
YoY Change -20.76% -17.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.134M $5.426M
YoY Change 59.34% 32.39%
Accrued Expenses $707.4K $693.7K
YoY Change 22.04% 39.18%
Deferred Revenue $29.31M $31.01M
YoY Change 86.7% 219.72%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.15M $37.13M
YoY Change 79.84% 159.24%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $4.750M $7.149M
YoY Change -71.06% -68.34%
Total Long-Term Liabilities $8.126M $10.53M
YoY Change -58.94% -59.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.15M $37.13M
Total Long-Term Liabilities $8.126M $10.53M
Total Liabilities $43.28M $47.66M
YoY Change 10.02% 18.32%
SHAREHOLDERS EQUITY
Retained Earnings -$152.2M -$144.8M
YoY Change 23.76% 25.0%
Common Stock $154.8M $151.0M
YoY Change 9.23% 7.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.731M $6.206M
YoY Change
Total Liabilities & Shareholders Equity $46.01M $53.86M
YoY Change -20.76% -17.03%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$7.367M -$7.768M
YoY Change 3.62% -0.64%
Depreciation, Depletion And Amortization $254.7K $230.1K
YoY Change 127.39% 148.78%
Cash From Operating Activities -$9.418M $4.210M
YoY Change 43.95% -82.49%
INVESTING ACTIVITIES
Capital Expenditures $233.4K $347.7K
YoY Change -156.58% -38.75%
Acquisitions
YoY Change
Other Investing Activities $6.695M -$2.759M
YoY Change -119.13%
Cash From Investing Activities $6.461M -$3.212M
YoY Change -118.25% 413.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.188M 3.895K
YoY Change 14487.13% -85.82%
NET CHANGE
Cash From Operating Activities -9.418M 4.210M
Cash From Investing Activities 6.461M -3.212M
Cash From Financing Activities 2.188M 3.895K
Net Change In Cash -768.4K 1.002M
YoY Change -98.17% -95.73%
FREE CASH FLOW
Cash From Operating Activities -$9.418M $4.210M
Capital Expenditures $233.4K $347.7K
Free Cash Flow -$9.651M $3.862M
YoY Change 57.45% -83.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.47
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.87
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.15
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.23
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2194784
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1065329
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25247354
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24282743
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25255154
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25255154
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34058
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15200000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
727-1755
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CAPR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25269926
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10605528
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9603242
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
34566342
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31818020
CY2023Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
875092
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
919892
CY2023Q1 us-gaap Assets Current
AssetsCurrent
46594542
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42888734
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4811044
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2189651
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2349974
CY2023Q1 us-gaap Other Assets
OtherAssets
268172
CY2022Q4 us-gaap Other Assets
OtherAssets
268172
CY2023Q1 us-gaap Assets
Assets
53863409
CY2022Q4 us-gaap Assets
Assets
50094910
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5407016
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4834683
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18716
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
89234
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
693652
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31012773
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17980599
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
37132157
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23586555
CY2023Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1699682
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5449062
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9467932
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10525003
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14722261
CY2023Q1 us-gaap Liabilities
Liabilities
47657160
CY2022Q4 us-gaap Liabilities
Liabilities
38308816
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25255154
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
25255
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25241
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
150934085
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148735420
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
94986
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105244
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144848077
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137079811
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53863409
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50094910
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2986696
CY2023Q1 us-gaap Revenues
Revenues
2986696
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7661519
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5115699
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3509885
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2715835
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11171404
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7831534
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8184708
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7831534
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
416442
CY2022Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
13440
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
416442
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13440
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7778524
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7818094
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25247354
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24282743
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1065329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27465
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24642666
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7768266
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-7818094
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
230101
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92490
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2194784
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1065329
CY2023Q1 capr Noncash Lease Expenses
NoncashLeaseExpenses
-6452
CY2022Q1 capr Noncash Lease Expenses
NoncashLeaseExpenses
72734
CY2022Q1 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-34753
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-44800
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-216691
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
572333
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
407203
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-70518
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-24540
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
9013304
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4210086
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24046566
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34803580
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32045000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
347690
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
567616
CY2023Q1 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
105425
CY2022Q1 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
57744
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3211695
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-625360
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3895
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27465
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3895
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27465
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1002286
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
23448671
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10605528
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58333945
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
45200000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41400000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023Q1 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2023Q1 us-gaap Depreciation
Depreciation
230101
CY2022Q1 us-gaap Depreciation
Depreciation
92490
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6208374
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5769655
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1397330
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1181625
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4811044
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2022Q1 capr Grant Income
GrantIncome
0
CY2023Q1 capr Grant Income
GrantIncome
0
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7700000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5100000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7800000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7800000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7971557
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5674191
CY2023Q1 capr Amortized Cost Of Marketable Securities
AmortizedCostOfMarketableSecurities
34471356
CY2023Q1 capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25255154
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2023Q1 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2023Q1 capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1756664
CY2023Q1 capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
45300000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
601801
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
765986
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
710259
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
547948
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2625994
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
232660
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2393334
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
693652
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1699682
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2393334
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M9D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0536
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2200000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2400000
CY2023Q1 capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18716
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
89234

Files In Submission

Name View Source Status
capr-20230331_cal.xml Edgar Link unprocessable
capr-20230331_pre.xml Edgar Link unprocessable
capr-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20230331_lab.xml Edgar Link unprocessable
0001558370-23-009521-index-headers.html Edgar Link pending
0001558370-23-009521-index.html Edgar Link pending
0001558370-23-009521.txt Edgar Link pending
0001558370-23-009521-xbrl.zip Edgar Link pending
capr-20230331.xsd Edgar Link pending
capr-20230331x10q.htm Edgar Link pending
capr-20230331xex31d1.htm Edgar Link pending
capr-20230331xex31d2.htm Edgar Link pending
capr-20230331xex32d1.htm Edgar Link pending
capr-20230331xex32d2.htm Edgar Link pending
capr-20230331x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending